What kind of targeted drug is cabozantinib and what diseases is it used for?

Cabozantinib, also known as 184 targeted drug, is a new multi-target small molecule tyrosine kinase inhibitor developed by Exelixis Biopharmaceutical Company in the United States. Since the drug was launched in the United States in November 2012, it has attracted widespread attention due to its unique multi-target mechanism of action and its remarkable efficacy in the treatment of various cancers.

Cabotinib can simultaneously inhibit multiple targets related to tumor growth, angiogenesis and metastasis, includingMET, VEGFR1/2/3, ROS1, RET, AXL, NTRK, KIT, etc. These targets play an important role in different types of cancer. By inhibiting the tyrosine kinase activity of these targets, cabozantinib can block the proliferation, migration and invasion of tumor cells and inhibit tumor angiogenesis, thereby achieving the purpose of treating tumors.

In terms of clinical application, cabozantinib has been approved for the treatment of a variety of malignancies, including unresectable malignant locally advanced or metastatic medullary thyroid cancer, advanced renal cancer that has failed Sutent therapy, and locally advanced or metastatic differentiated thyroid cancer that has progressed after frontline anti-VEGF targeted therapy and is refractory to radioactive iodine. In addition, cabozantinib has also demonstrated good clinical effects in the treatment of liver cancer, non-small cell lung cancer, soft tissue sarcoma, prostate cancer, breast cancer, ovarian cancer and other cancers, especially in the control of cancer bone metastasis.

However, it is worth noting that cabozantinib may also cause some side effects during use, such as diarrhea, fatigue, loss of appetite, high blood pressure, oral ulcers, etc. Therefore, when using cabozantinib for treatment, patients should strictly follow the doctor's instructions and monitor relevant indicators regularly to detect and deal with possible adverse reactions in a timely manner.

Overall, cabozantinib, as a multi-target targeted drug, plays an important role in the treatment of various cancers and provides patients with new treatment options. However, due to its high price and risk of side effects, full evaluation and weighing is required before use.